Cue Biopharma has dosed the first subject in a Phase I dose escalation clinical trial of its drug candidate, CUE-102, as a single agent to treat Wilms’ Tumor 1 (WT1)-positive recurrent/metastatic cancer patients.
In the initial stage, the trial will focus on gastric, colorectal, ovarian, and pancreatic cancers.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataThe open-label, multicentre, dose escalation and expansion trial will analyse the safety, tolerability, anti-tumour activity, and immunogenicity of CUE-102.
It will enrol nearly 50 HLA-A*0201-positive WT1-positive recurrent/metastatic cancer patients who have failed standard treatments.
The second candidate from the CUE-100 series of interleukin 2 (IL-2)-based biologics, CUE-102, is in the development stage as a new therapeutic fusion protein.Â
It is said to selectively trigger tumour antigen-specific T cells for treating WT1-expressing cancers.
CUE-102 comprises two WT1 peptide-presenting human leukocyte antigen (HLA) molecules, four affinity-attenuated IL-2 molecules, and an effector attenuated human immunoglobulin G (IgG1) Fc domain.Â
Cue Biopharma CEO Dan Passeri said: “Initiating this Phase I clinical study of CUE-102 at a starting dose of 1mg/kg, a clinically active dose in our Phase I CUE-101 clinical trial for HPV+ head and neck cancer, is an important step forward in demonstrating the modularity of our Immuno-STAT platform and the broader clinical potential of our CUE-100 series of biologics.
“We believe, given the preservation of the core molecular framework between CUE-102 and CUE-101 with the primary exception of the tumour-specific epitope, initiating the dose escalation trial at 1mg/kg will result in reduced time and cost to evaluate tolerability at therapeutically active doses.”
WT1 is a known onco-foetal protein over-expressed in various cancers including hematologic malignancies and solid tumours such as glioblastoma, gastric, pancreatic, endometrial, breast, lung, ovarian, colorectal, and acute myeloid leukaemia.
